La morbidité compétitive et son impact sur l'espérance de vie : Évaluation et prise en compte dans la décision thérapeutique du cancer localisé de la prostate

Progres en Urologie

Volumn 11, Issue 6, 2001, Pages 1195-1204

  Soulié, Michel ^a   Villers, Arnauld ^b   Richaud, Pierre ^b   Prapotnich, Dominique ^b   Ruffion, Alain ^b   Grosclaude, Pascale ^b  

^a CHU RANGUEIL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; LIFE EXPECTANCY; MALE; MORBIDITY; MORTALITY; PROSTATE TUMOR; REVIEW;

HUMANS; LIFE EXPECTANCY; MALE; MORBIDITY; PROSTATIC NEOPLASMS;

EID: 0347708784     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. ADOLFSSON J., STEINECK G., WHITMORE W.F. JR. Recent results of management of palpable clinically localized prostate cancer. Cancer, 1933, 72. 310-322.
2. ALBERTSEN P., FRYBACK D.G., STORER B.E., KOLON T.F., FINE J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J. Urol., 1996, 156, 127-132.
3. ALBERTSEN P.C., HANLEY J.A., GLEASON D.F., BARRY M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. J.A.M.A., 1998, 280, 1008-1010.
4. ALBERTSEN P. When is a death from prostate cancer not a death from prostate cancer. Editorial. J. Natl. Cancer Inst., 2000, 92, 590-591.
5. ALBERTSEN P., WALTERS P.C., HANLEY J.A. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J. Urol., 2000, 163, 519-523.
6. ASTRO. Consensus statement : guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37, 1035-1041.
7. AUS G., PILEBLAD E., HUGOSSON J. Impact of competing mortality on the cancer-related mortality in localized prostate cancer. Urology, 1995, 46, 672-675.
8. CARTER H.B., EPSTEIN J.I., PARTIN A.W.. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with non palpable disease. Urology, 1999, 53, 126-130.
9. CHODAK G.W., THISTED R.A., GERBER G.S., JOHANSSON J.E., ADOLFSSON J., JONES G.W., CHISHOLM G.D., MOSKOVITZ B., LIVNE P.M., WARNER J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med., 1994, 330, 242-248.
10. CHODAK G.W. Comparing treatments for localized prostate cancer-persisting uncertainty (editorial). J.A.M.A., 1998, 280, 1008-1010.
11. FOWLER J.E. JR., TERREL F.L., RENFROE D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J. Urol., 1996, 156, 1714-1718.
12. GANN P.H., HENNEKENS C.H., STAMPFER M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J.A.M.A., 1995, 273, 289-294.
13. ISELIN C., ROBERTSON J.E., PAULSON D.F. Radical perineal prostatectomy : oncological outcome during a 20 year period. J. Urol., 1999, 161, 163-168.
14. KOCH M.O., MILLER D.A., BUTLER R., LEBOS L., COLLINGS D., SMITH J.A. Jr. Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis. Urology, 1998, 51, 197-202.
15. KRONGRAD A., LAI H., LAI S. Competing risks of mortality in prostate cancer. J. Urol., 1997, 158, 865-868.
16. KRONGRAD A., LAI H., LAI S. Hospitalization, inpatient physical therapy and institutionalization after hospital discharge of prostate cancer patients in South Florida. J. Urol., 1998, 159, 888-892.
17. LITWIN M.S., KAHN K.L., RECCIUS N. Why do sicker patients cost more? A charge-based analysis of patients undergoing prostatectomy. J. Urol., 1993, 149, 84-88.
18. LITTRUP P.J. Future benefits and cost-effectiveness of prostate carcinoma screening. Cancer, 1997, 80, 1864-1870.
19. MENEGOZ F., CHERIE-CHALLINE L. Le cancer de la prostate. In: le cancer en France : incidence et mortalité. Situation en 1995. Evolution entre 1975 et 1995. Paris, Réseau Francim, la Documentation Française, 1998, pp. 100-103.
20. MERRIL R.M., STEPHENSON R.A. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J. Urol., 2000, 163, 503-510.
21. KEATS A.S. The ASA classification of physical status. A recapitulation. Anesthesiology, 1978, 49, 233-236.
22. NEWSCHAFFER C.J. Re: The impact of co-morbidity on life expectancy among men with localized prostate cancer (letter; comment). J. Urol., 1997, 153 : 964-965.
23. NEWSCHAFFER C.J., OTANI K., MacDONALD M.K., PENTBERTHY L.T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J. Natl. Cancer Inst., 2000, 92, 613-621.
24. POST P.N., KIL P.J.M., HENDRIKX A.J.M., JANSSEN-HEIJNEN M.L.G., CROMMELIN M.A., COEBERGH J.W.W. Comorbidity in patients with prostate cancer and its relevance to treatment choice. Br. J. Urol., 1999, 84 : 652-656.
25. PRIOR T., WAXMAN J. Localized prostate cancer : can we do better ? Br. Med. J., 2000, 320 : 69-70.
26. POUND C.R., PARTIN A.W., EISENBERGER M.A., CHAN D.W., PEARSON J.D., WALSH P.C. Natural history of progression after PSA elevation following radical prostatectomy. J.A.M.A., 1999, 281 : 1591-1597.
27. REPETTO L., VENTURINO A., VERCELLI M., GIANNI W., BIANCARDI V., CASELLA C., GRANETTO C., PARODI S., ROSSO R., MARIGLIANO V. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer, 1998, 82, 760-765.
28. SATARIANO W.A., RAGLAND K.E., VAN DER EEDEN S.K. Cause of death in men diagnosed with prostate cancer. Cancer, 1998, 83, 1180-1188.
29. Statistiques des causes médicales de décès. INSERM eds. Paris, 1997.
30. STAMEY T.A., MacNEAL J.E., YEMOTO C.M., SIGAL B.M., JOHNSTONE I.M. Biological determinants of prostate cancer progression in men with prostate cancer. J.A.M.A., 1999, 281 : 1395-1400.
31. STAMEY T.A., YEMOTO C.M., MacNEAL J.E., SIGAL B.M., JOHNSTONE I.M. Prostate cancer is highly predictable : a pronostic equation based on all morphological variables in radical prostatectomy. J. Urol., 2000, 163 : 1155-1160.
32. STIER D.M., GREENFIELD S., LUBECK D.P., DUKES K.A., FLANDERS S.C., HENNING J.M., WEIR J., KAPLAN S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology, 1999, 54, 424-429.
33. THUMERELLE P.J. Taux bruts de mortalité et espérance de vie. In : atlas de la Santé en France, vol. 1. Les causes de décès. G. Salem, S. Rican, E. Jougla Paris, John Libbey Eurotext., 2000, pp. 17-21.
34. VILLERS A., GROSCLAUDE P., HAILLOT O., ABBOU C.C., RICHARD F., BOCCON-GIBOD L. Dépistage du cancer de la prostate (I) : évolution des connaissances et des pratiques depuis la conférence de consensus de 1989. Prog. Urol., 1997, 7, 508-515.
35. VILLERS A., SOULIE M., HAILLOT O., BOCCON-GIBOD L. Dépistage du cancer de la prostate (III) : Facteurs de risque, histoire naturelle, évolution sans traitement. Caractéristiques des cancers dépistés. Prog. Urol., 1997, 7, 655-661.
36. WALSH P.C. The natural history of localized prostate cancer : a guide to therapy. In Campbell's in Urology, vol. 3. P.C. Walsh, A.B. Retik, E.D. Vaughan, A.J. Wein eds. 1998, pp. 2539-2546.